Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Neoplasms 3Neoplasm Metastasis 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 3Gemcitabine 3durvalumab 2Cystoscopy 2toripalimab 1pembrolizumab 1enfortumab vedotin 1cemiplimab 1apaziquone 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Standard of Care 1Oncolytic Virotherapy 1Nivolumab 1Magnetic Resonance Imaging 1Interferons 1Imiquimod 1Histamine Antagonists 1Electrocardiography 1Docetaxel 1Diphenhydramine 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Biopsy 1BCG Vaccine 1Acetaminophen 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × ALT-801 × Genitourinary × Clear all
NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

Phase 1/2 Terminated
12 enrolled 13 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡